Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has submitted a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, stating that the promoters and promoter group have not acquired any shares or voting rights in the company, but have experienced a passive reduction in shareholding due to the allotment of 2,11,86,440 equity shares to non-promoters under a QIP issue.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has announced the outcome of its Board Meeting held on September 1, 2026, where it approved the issuance of up to 82,10,786 equity shares at an issue price of Rs. 408 per share, aggregating up to Rs. 335,00,00,688, to be issued on a private placement basis.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has announced the outcome of the Fund Raising Committee meeting held on August 28, 2026, for the allotment of equity shares through a Qualified Institutions Placement (QIP). The committee approved the issue and allotment of 2,11,86,440 equity shares at an issue price of Rs. 354 per equity share, aggregating to Rs. 749,99,99,760. The paid-up equity share capital of the company stands increased from Rs. 10,89,65,265 to Rs. 13,01,51,705.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has closed its Qualified Institutional Placement (QIP) issue period and allotted 2,11,86,440 equity shares to eligible QIBs at Rs. 354 per share, including a premium of Rs. 353 per share.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/09/2026, inter alia, to consider and approve raising funds through issue of equity shares and/or convertible warrants through preferential issue on a private placement basis.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has approved a qualified institutions placement (QIP) of equity shares to raise funds, with a floor price of ₹ 372.57 per share and an option to offer a discount of up to 5%.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has announced the audited financial statements for the year ended March 31, 2026, along with the audit reports issued by the Statutory Auditor. The financial statements are available on the company's website.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has amended its Articles of Association, specifically deleting a clause related to share valuation by a registered valuer or approved valuer.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has announced an amendment to its Articles of Association, specifically deleting a clause related to share price determination by a registered valuer. The change allows for the sale of shares to any person, either for cash or other consideration. The amendment was approved by the company's shareholders at an Extraordinary General Meeting on August 22, 2026.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has announced the outcome of a postal ballot, where shareholders voted on three special resolutions. The resolutions include raising funds by issuing equity shares through a qualified institutions placement, amending the articles of association, and private placement of non-convertible debentures and/or debt securities. All three resolutions were passed with requisite majority.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has announced the voting results and scrutinizer's report on postal ballot through e-voting for passing of special resolutions. The resolutions include raising funds by issue of equity shares through qualified institutions placement, amendment to the articles of association, and private placement of NCDs and/or debt securities. The resolutions were passed with requisite majority.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd held an Extra-ordinary General Meeting (EGM) on August 22, 2026, where shareholders approved several resolutions, including the approval of Material Related Party Transactions with Promoter/Promoter group entities, amendment to the Articles of Association, and private placement of NCDs and/or debt securities.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd held an EGM on 22nd August 2026, where 56 members were present. The meeting approved three resolutions: approval of material related party transactions, amendment to the articles of association, and private placement of NCDs and/or debt securities. The resolutions were passed with the requisite majority.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd submitted call recordings of the investor/analyst conference call held on August 10, 2026, as per Regulation 30 and Regulation 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has announced the publication of un-audited financial results for the quarter ended 30.06.2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has released its Q1 FY2026-27 investor presentation, showing a 22.1% year-on-year growth in top line to Rs. 43.8 crores, with EBITDA increasing 49.4% to Rs. 20.8 crores and PAT improving 22.1% to Rs. 11.1 crores. The company has also made significant strides in its inorganic expansion initiatives, including the acquisition of Sanofi's brands and MicroBiopharm in Japan.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of ₹1,106.67 lakhs and earnings per share of ₹1.02.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has announced its unaudited standalone financial results for the quarter ended June 30, 2026, with a net profit of ₹1,106.67 lakhs and earnings per share of ₹1.02.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has received a disclosure under Regulation 10(6) of SEBI (SAST) Regulations, 2011, regarding an inter-se transfer of shares among promoters and promoter group members, with Sachin D. Patel acquiring 5,23,560 equity shares from Pharmaceutical Business Group India Limited at Rs. 382 per share.

Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd has scheduled a conference call to discuss its 1QFY27 financial performance on August 10, 2026.